Fluoxetine and infantile hypertrophic pylorus stenosis: A signal from a birth defects - Drug exposure surveillance study

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 8, 2010, Pages 808-813

  Bakker, Marian K ^a   De Walle, Hermien E K ^a   Wilffert, Bob ^b   De Jong Van Den Berg, Lolkje T W ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Case control surveillance; Fluoxetine; Infantile hypertrofic pylorus stenosis; Signal detection

Indexed keywords

FLUOXETINE; FOLIC ACID;

ARTICLE; BIRTH DEFECT; CASE CONTROL STUDY; CONTROLLED STUDY; ETHNICITY; FAMILY HISTORY; FIRST TRIMESTER PREGNANCY; GENETIC DISORDER; HUMAN; MALFORMATION SYNDROME; MATERNAL AGE; MATERNAL SMOKING; NETHERLANDS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PYLORUS STENOSIS; REGISTER;

ABNORMALITIES, DRUG-INDUCED; CONFIDENCE INTERVALS; FEMALE; FLUOXETINE; HUMANS; INFANT; INFANT, NEWBORN; MATERNAL AGE; ODDS RATIO; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRODUCT SURVEILLANCE, POSTMARKETING; PYLORIC STENOSIS, HYPERTROPHIC; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 77956639271     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1964     Document Type: Article

References (18)

1. Robert E, Vollset SE, Botto L, et al. Malformation surveillance and maternal drug exposure: the MADRE project. Int J Risk Saf Med 1994; 6: 75-118.
2. Mitchell AA. Systematic identification of drugs that cause birth defects - a new opportunity. N Engl J Med 2003; 349(26): 2556-2559.
3. Martinez-Frias ML. Postmarketing analysis of medicines: methodology and value of the spanish case-control study and surveillance system in preventing birth defects. Drug Saf 2007; 30(4): 307-316. (Table Presented)
4. Kaufman DW, Rosenberg L, Mitchell AA. Signal generation and clarification: use of case-control data. Pharmacoepidemiol Drug Saf 2001; 10(3): 197-203.
5. WHO Collaborating Centre for Drugs Statistics Methodology. ATC/DDD Index. http://www.whocc.no/atc-ddd-index/ [Accessed on 2 December 2004].
6. Reefhuis J, Zandwijken GR, DeWalle HE, Cornel MC. Birth defect and risk factor surveillance in the northern and southwestern Netherlands. Community Genet 1999; 2(2-3): 97-108.
7. Bakker MK, De Walle HE, Dequito A, van den Berg PB, de Jong-van den Berg LT. Selection of controls in case-control studies on maternal medication use and risk of birth defects. Birth Defects Res A Clin Mol Teratol 2007; 79 (9): 652-656.
8. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008; 66(5): 695-705.
9. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354(6): 579-587. (Pubitemid 43209105)
10. Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf 2005; 28(7): 565-581.
11. Eurocat Northern Netherlands. Prevalence of congenital malformations in the Northern Netherlands 1981-2007. Available at: http://www.rug.nl/umcg/ faculteit/disciplinegroepen/MedischeGenetica/Eurocat/professionals/tabellen [Accessed on 29 May 2009].
12. MacMahon B. The continuing enigma of pyloric stenosis of infancy: a review. Epidemiology 2006; 17(2): 195-201.
13. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996; 16(7): 2352-2364.
14. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132(1): 397-414.
15. Nebigil CG, Etienne N, Schaerlinger B, Hickel P, Launay JM, Maroteaux L. Developmentally regulated serotonin 5-HT2B receptors. Int J Dev Neurosci 2001; 19(4): 365-372.
16. Palvimaki EP, Roth BL, Majasuo H, et al. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl) 1996; 126(3): 234-240.
17. Kallen B, Olausson PO. No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy. Int J Med Sci 2006; 3(3): 106-107.
18. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. Firsttrimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356(26): 2675-2683.